This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
== External links == "einsteinium (Es) - chemical element". Britannica.com. Retrieved 23 May 2017. "mendelevium (Md) - chemical element". Britannica.com. Retrieved 23 May 2017. "synthetic elements". Encyclopedia2.thefreedictionary.com. Retrieved 23 May 2017. "It's Elemental - The Element Fermium". Education.jlab.org. Retrieved 23 May 2017. Kulkarni, Mayuri (15 June 2009). "A Complete List of Man-made Synthetic Elements". ScienceStuck. Retrieved 15 May 2019.
Moreover, when considering participants in research, it is also important to look at labelling and stigma attached as published research can be read and used by the public and cause bias, despite research limitations if they are not addressed and thought-out thoroughly by a reader, and cause people to push labels on people, as Voronka discusses how research can be used and influenced to make homelessness mental health condition instead of a result of structural and capitalist policies, as well as can create a stigma around people deemed so-called at-risk, as Corcoran, Malaspina, and Hercher discuss, raising questions around when to intervene and how research can be harmful.
=== Surgery === Corneal transplant surgery may be difficult due to the peripheral thinning of the cornea, even with large and off-center grafts. Therefore, surgery is usually reserved for people that do not tolerate contact lenses. Several different surgical approaches may be taken, and no one approach is currently established as the standard. Examples of surgical procedures used for PMD include: wedge resection, lamellar crescentic resection, penetrating keratoplasty, lamellar keratoplasty, epikeratoplasty and intracorneal segments. Transplantation of the entire thickness of the cornea (penetrating keratoplasty) may be performed if there is enough normal tissue present. However, if there is not enough normal tissue present, then attaching the graft is difficult. New surgical techniques are in evaluation such as Intrastromal lamellar Keratoplasties and Sclerocorneal Intrastromal Lamellar Keratoplasty (SILK), these techniques allow thickening of the inferior peripheral cornea and steepening of the vertical meridien. Due to the thinning of the cornea, people with PMD are poor candidates for procedures such as LASIK and photorefractive keratectomy.
Men have experienced difficulties in accepting and communicating about FM, as it was sometimes seen as a "woman's disease" and could thus impact their self-image. Well-known people who have had FM include Lady Gaga, Sinead O'Connor, Mary McDonough, Janeane Garofalo, Rosie Hamlin, Kirsty Young, Lena Dunham, and Morgan Freeman. Cricketer Don Bradman was diagnosed with fibrositis, an early term for fibromyalgia.
Dynamic warm-ups (performed with greater than 20% of maximal effort) enhance strength and power in upper-body exercises. When properly warmed up the lifter will have more strength and stamina since the blood has begun to flow to the muscle groups. Pulse raisers do not have any effect on either 1RM or submaximal training. Static stretching induces strength loss, and should therefore probably not be performed before strength training. Resistance training functions as an active form of flexibility training, with similar increases in range of motion when compared to performing a static stretching protocol. Static stretching, performed either before or after exercise, also does not reduce muscle soreness in healthy adults.
Sources: en.wikipedia.org
== Membership == In 1975, chairman Frank Zeidler claimed that SPUSA had around 500 members nationwide. SPUSA saw growth during the late 1970s and early to mid-1980s, expanding from around 600 members to around 1,700 members. In 2008, WMNF claimed that SPUSA had around 3,000 members. However, in 2010, CommonDreams wrote that SPUSA had only 1,000 members, and party members described that as an increase in membership. In May 2011, The New York Times stated that SPUSA had "about 1,000 members nationally". In February 2012, The Root stated that SPUSA had "around 1,500" members.
According to these rules, compounds with the most ionic character will have large positive ions with a low charge, bonded to a small negative ion with a high charge. More generally HSAB theory can be applied, whereby the compounds with the most ionic character are those consisting of hard acids and hard bases: small, highly charged ions with a high difference in electronegativities between the anion and cation. This difference in electronegativities means that the charge separation, and resulting dipole moment, is maintained even when the ions are in contact (the excess electrons on the anions are not transferred or polarized to neutralize the cations). Although chemists classify idealized bond types as being ionic or covalent, the existence of additional types such as hydrogen bonds and metallic bonds, for example, has led some philosophers of science to suggest that alternative approaches to understanding bonding are required. This could be by applying quantum mechanics to calculate binding energies.
== USDA 1902-1922 == Lore Rogers's research experience under Russell at Wisconsin and at the New York State Agricultural Experiment Station provided the background he needed to land a government position in 1902 with the USDA. The office was then designated as the Dairy Division of the Bureau of Animal Industry.
Adult linear IgA disease Bullous pemphigoid Bullous lupus erythematosus Childhood linear IgA disease (chronic bullous disease of childhood) Cicatricial pemphigoid (benign mucosal pemphigoid, benign mucous membrane pemphigoid, ocular pemphigus, scarring pemphigoid) Dermatitis herpetiformis (Duhring disease) Dyshidrosis (recurrent vesicular palmoplantar dermatitis, acute vesiculobullous hand eczema, dyshidrotic dermatitis, pompholyx) Endemic pemphigus (endemic pemphigus foliaceus, fogo selvagem) Epidermolysis bullosa acquisita Grover's disease (benign papular acantholytic dermatosis, persistent acantholytic dermatosis, transient acantholytic dermatosis) IgA pemphigus Intraepidermal neutrophilic IgA dermatosis Localized cicatricial pemphigoid (Brunsting–Perry cicatricial pemphigoid) Paraneoplastic pemphigus Pemphigus erythematosus (Senear–Usher syndrome) Pemphigus foliaceus Pemphigus herpetiformis (acantholytic herpetiform dermatitis, herpetiform pemphigus, mixed bullous disease, pemphigus controlled by sulfapyridine) Pemphigoid nodularis Pemphigus vegetans Pemphigus vegetans of Hallopeau Pemphigus vegetans of Neumann Pemphigus vulgaris Vesicular pemphigoid Vulvar childhood pemphigoid
== Lexicology == The Latin term impotentia coeundi describes simple inability to insert the penis into the vagina; it is now mostly replaced by more precise terms, such as erectile dysfunction (ED). The study of ED within medicine is covered by andrology, a sub-field within urology. Research indicates that ED is common, and it is suggested that approximately 40% of males experience symptoms compatible with ED, at least occasionally. The condition is also on occasion called phallic impotence. Its antonym, or opposite condition, is priapism.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.